|
Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen …
The Providence Journal The report also finds that novel late-stage emerging disease-modifying therapies (DMTs) for the treatment of MS–Genzyme/Bayer HealthCare’s Lemtrada, Biogen Idec/AbbVie’s daclizumab and Roche/Genentech’s ocrelizumab–will generally be reserved for … |
|
Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen …
PR Newswire (press release) The report also finds that novel late-stage emerging disease-modifying therapies (DMTs) for the treatment of MS—Genzyme/Bayer HealthCare’s Lemtrada, Biogen Idec/AbbVie’s daclizumab and Roche/Genentech’s ocrelizumab—will generally be reserved for … |
|
安斯泰来在美推出他克莫司缓释胶囊（Astagraf XL）
生物谷 2013年8月24日讯/生物谷BIOON/ –安斯泰来（Astellas）8月23日宣布，在美国推出Astagraf XL（他克莫司缓释胶囊，tacrolimus extended release capsules），该药与霉酚酸酯（MMF）及皮质类醇联用、结合或无巴利昔单抗 … |
|
Astellas Pharma launches Astagraf XL in US markets
pharmabiz.com The recommended starting dose of Astagraf XL with basiliximab induction is 0.15 mg/kg once-daily. The recommended starting dose of Astagraf XL without basiliximab induction is 0.1 mg/kg once-daily (pre-operative) and 0.2 mg/kg once-daily (post … Astellas’ Astagraf XL Launched in U.S. – Analyst BlogNASDAQ Astellas Pharma launches once-daily oral tacrolimus formulation in USPharmaceutical Business Review |
|
Astellas’ Astagraf XL Launched in U.S. – Analyst Blog
NASDAQ Astagraf XL was approved in the U.S. in Jul 2013 for the prophylaxis of organ rejection in patients receiving a kidney transplant used with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction. As per Astellas … ASTELLAS PHARMA INC : ASTAGRAF XLTM (tacrolimus extended-release …4-traders (press release) Astellas Pharma launches once-daily oral tacrolimus formulation in USPharmaceutical Business Review |
Astellas Astagraf XL Launched in U.S.Zacks.comAstagraf XL was approved in the U.S. in Jul 2013 for the prophylaxis of organ rejection in patients receiving a kidney transplant used with mycophenolate mofetil (MMF) and corticosteroids, with or without b…
ASTELLAS PHARMA INC : ASTAGRAF XLTM (tacrolimus extended-release …4-traders (press release)The recommended starting dose of ASTAGRAF XL with basiliximab induction is 0.15 mg/kg once-daily. The recommended starting dose of ASTAGRAF XL without basilixi…
|
ASTAGRAF XL™ (tacrolimus extended-release capsules), Prophylaxis of Organ …
Sacramento Bee The recommended starting dose of ASTAGRAF XL with basiliximab induction is 0.15 mg/kg once-daily. The recommended starting dose of ASTAGRAF XL without basiliximab induction is 0.1 mg/kg once-daily (pre-operative) and 0.2 mg/kg once-daily … |
|
ASTAGRAF XL™ (tacrolimus Extended-release Capsules), Prophylaxis Of …
Daily Markets (press release) The recommended starting dose of ASTAGRAF XL with basiliximab induction is 0.15 mg/kg once-daily. The recommended starting dose of ASTAGRAF XL without basiliximab induction is 0.1 mg/kg once-daily (pre-operative) and 0.2 mg/kg once-daily … |
|
ASTAGRAF XL™ (tacrolimus extended-release capsules), Prophylaxis of Organ …
PR Newswire (press release) The recommended starting dose of ASTAGRAF XL with basiliximab induction is 0.15 mg/kg once-daily. The recommended starting dose of ASTAGRAF XL without basiliximab induction is 0.1 mg/kg once-daily (pre-operative) and 0.2 mg/kg once-daily … |